Sex and outcomes of patients with microsatellite instability-high and <i>BRAF</i> V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are the gold standard therapy in patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). A significant proportion of patients show resistance, making the identification of determinants of response crucial. Growing evidence supports the role of sex in determining susceptibility to anticancer therapies, but data is lacking for patients with MSI-H CRC.

Methods

In this real-world cohort comprising 624 patients with MSI-H mCRC receiving ICIs, we investigated the impact of sex on patients' outcomes, overall and according to RAS-BRAF mutational status or type of treatment (anti-PD-(L)1 with or without anti-CTLA-4 agents). We then investigated these associations

SUBMITTER: Nasca V 

PROVIDER: S-EPMC11815414 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature